New combo tackles brain tumors: drug plus radiation
NCT ID NCT02015117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the drug trametinib, which blocks enzymes that help cancer cells grow, given with or without whole-brain radiation. The goal is to find the safest dose and see how well the drug reaches the brain. Ten adults with brain metastases from other cancers are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trametinib (a targeted cancer drug)
- What this could lead to
- If it works, this could point toward a new way to treat brain metastases by combining a targeted drug with radiation.
- What could go wrong
- This is a very early phase 1 trial with only 10 participants, so it is mainly checking safety and dosing. It may not lead to a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- Brain zap study: will precision radiation save your memory?
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Radiation before brain surgery may stop cancer's return
- Smart drug targets breast cancer in the brain
- New hope for tough breast cancers: drug combo targets tumors in body and brain